OMER - Omeros slips to 52-week low as stock down 9%

Omeros Corp. (NASDAQ:OMER) continues to struggle as the biopharma hit a new 52-week low of $2.16 on Thursday. Shares are down 9%. The stock has struggled in 2022. Year to date, Omeros is down more than 68%. Omeros (OMER) shares have been weighed down since October 2021 when the U.S. FDA issued a Complete Response Letter for a Biologics License Application for narsoplimab for hematopoietic stem cell transplant-associated thrombotic microangiopathy (HSCT-TMA). Omeros is appealing that decision. Despite the challenges Omeros (OMER) is facing, see why Seeking Alpha contributor Out of Ignorance has a sanguine outlook for the company.

For further details see:

Omeros slips to 52-week low as stock down 9%